phrykt

Alaunos Therapeutics, Inc. (TCRT): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of TCRT were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No TCRT insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TCRT short interest

Moderate short interest. 7.3% of TCRT shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 2236%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 184,372 TCRT shares were sold short, 7.3% of the shares outstanding, down 77.5% from the report before. At the average daily volume of 7.65M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

7.26%May 15Oct 3037.0%

Days to cover

1.0May 15Oct 301.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026184,3727.26%-77%7.65M1.0
Oct 15, 2026818,60232.22%+8308%30.93M1.0
Sep 30, 20269,7360.38%+60%4.31M1.0
Sep 15, 20266,0750.24%+6%10,3201.0
Aug 31, 20265,7070.22%-54%16,4361.0
Aug 14, 202612,5120.49%+28%8,0721.6
Jul 31, 20269,7760.41%-27%10,0881.0
Jul 15, 202613,3190.56%-9%15,5731.0
Jun 30, 202614,6730.62%+26%13,9421.1
Jun 15, 202611,6070.49%-17%21,8441.0
May 29, 202613,9030.58%+76%24,0051.0
May 15, 20267,8930.33%-9%8,0331.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Alaunos Therapeutics company events

Alaunos Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Oct 23, 2026.

  1. Oct 23, 2026AnnouncementAs previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The… Filing
  2. Oct 21, 2026ListingBackground As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies… Filing
  3. Oct 13, 2026LeadershipAppointment of Directors In accordance with the Merger Agreement, on October 13, 2026, effective immediately after the effective time of the Second Merger, Peter Harwin was appointed to the Board as a director. Filing
  4. Oct 9, 2026ListingAs previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of… Filing
  5. Sep 22, 2026AgreementAlaunos Therapeutics, Inc. entered into a securities purchase agreement with the accredited investors named on the signature pages thereto, pursuant to which the Company agreed to sell and issue, in a registered direct offering, 380,469 shares of its common stock, par value $0.001 per share, at a… Filing
  6. Sep 17, 2026SharesChanged the rights of its shareholders. Filing
  7. Jun 29, 2026AnnouncementAlaunos Therapeutics, Inc. issued a press release announcing a new preclinical statistical analysis of liver weight adjusted for body fat percentage from the Company’s previously reported non-Good Laboratory Practice diet-induced obesity mouse Study 1 of ALN1003, the Company’s investigational oral… Filing
  8. May 26, 2026AnnouncementAlaunos Therapeutics, Inc. issued a press release announcing an integrated preclinical readout for ALN1003, the Company’s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. Filing
  9. May 18, 2026AnnouncementAlaunos Therapeutics, Inc. issued a press release announcing updated preclinical data from two non-GLP diet-induced obesity mouse studies evaluating ALN1003, the Company’s investigational oral metabolic therapeutic candidate for obesity and related metabolic disorders. Filing
  10. Apr 15, 2026ListingAlaunos Therapeutics, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in… Filing
  11. Mar 2, 2026AnnouncementAlaunos Therapeutics, Inc. issued a press release announcing positive preclinical proof-of-concept data from two non-GLP diet-induced obesity mouse studies evaluating ALN1003, the Company’s lead small-molecule drug candidate for treating obesity and related metabolic disorders. Filing
  12. Jan 8, 2026AnnouncementShareholder Nomination of Potential Board Member The Company notes the following developments regarding a group of stockholders that has filed Schedules 13D with the Securities and Exchange Commission: ▪ On October 30, 2025, the Group filed an initial Schedule 13D reporting beneficial ownership of… Filing
  13. Dec 23, 2025AnnouncementMade another announcement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Alaunos Therapeutics financials

Famous investors that hold TCRT

1 of the 50 well-known investors we track reported holding TCRT in their latest 13F filing. The largest position is Ken Griffin's, worth $12.3K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202613,968$12.3K0.0%+18%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TCRT in the last 120 days.

FiledHolderFormStake
Oct 15, 2026Fairmount Funds Management LLC13D20.0%
Oct 15, 2026Fairmount Funds Management LLC13D20.0%
Oct 15, 2026WaterMill Asset Management Corp.13D/A10.0%
Oct 15, 2026WaterMill Asset Management Corp.13D/A10.0%

Questions about Alaunos Therapeutics, Inc. (TCRT) stock

Are TCRT insiders buying or selling?

No TCRT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in TCRT?

As of Oct 30, 2026, 184,372 TCRT shares were sold short, 7.3% of the shares outstanding, down 77.5% from the report before. At the average daily volume of 7.65M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold TCRT?

1 of the 50 well-known investors we track reported TCRT in their latest 13F filing, including Ken Griffin. The largest position is worth $12.3K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.